Long-term safety of abrocitinib in moderate-to-severe atopic dermatitis: integrated analysis by age

Cork, M.J. orcid.org/0000-0003-4428-2428, Deleuran, M., Geng, B. et al. (8 more authors) (2025) Long-term safety of abrocitinib in moderate-to-severe atopic dermatitis: integrated analysis by age. The Journal of Allergy and Clinical Immunology: In Practice. ISSN 2213-2198

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2025 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article distributed under the terms of the Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords: JAK 1-selective inhibitor; age groups; herpes zoster; lymphopenia; major adverse cardiovascular events; thrombocytopenia; venous thromboembolism
Dates:
  • Published: 11 March 2025
  • Published (online): 11 March 2025
  • Accepted: 28 February 2025
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health
Funding Information:
Funder
Grant number
PFIZER INC.
70111305
PFIZER INC.
WI242083
Depositing User: Symplectic Sheffield
Date Deposited: 21 Mar 2025 09:40
Last Modified: 21 Mar 2025 09:40
Published Version: https://www.sciencedirect.com/science/article/pii/...
Status: Published online
Publisher: Elsevier BV
Refereed: Yes
Identification Number: 10.1016/j.jaip.2025.02.040
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics